Tempus expands collaboration with Moderna and Merck to support potential commercialization of intismeran autogene (V940/mRNA-4157)

Tempus said it has expanded and extended a multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel investigational therapy referenced under multiple names as it advances through development.

In a press release dated October 7, Tempus described the new effort as an “expanded, multi-year collaboration,” positioning it around commercialization readiness rather than near-term product launch timing. The announcement, distributed through Yahoo Finance, frames the collaboration as part of an effort to move the therapy toward market if it successfully reaches that stage.

Tempus said the collaboration is intended to support “potential commercialization” of intismeran autogene. The company did not specify in the post how far along the program is in clinical testing, what regulatory path is being targeted, or what commercialization milestones the parties expect to complete during the multi-year period.

The therapy at the center of the collaboration is identified by Tempus with three labels: intismeran autogene, V940, and mRNA-4157. Tempus did not provide additional technical detail in the announcement about how the therapy works, what patient population it is designed for, or what biomarkers or endpoints are being used to evaluate efficacy in studies.

For Moderna, the collaboration reinforces its position as a leading mRNA platform company, while also highlighting how its programs may be paired with tooling and operational capabilities from precision-medicine partners as therapies approach commercialization. Moderna trades on the Nasdaq under the ticker MRNA.

For Merck, participation indicates continued interest in mRNA-driven oncology and immunotherapy approaches, including efforts that rely on partners to translate clinical programs into scalable commercialization processes. The announcement named Merck broadly but did not spell out which Merck entity is involved or whether it is operating through a specific subsidiary for this work.

Tempus, which is listed on the Nasdaq under TEM, has built its business around data and technology for precision medicine. In this announcement, the company framed the partnership as supporting commercialization efforts for a specific investigational therapy, but it did not describe which operational components it would contribute, such as data systems, manufacturing coordination, companion diagnostics, distribution planning, or other readiness activities.

What is still unclear is how the parties will measure progress during the multi-year term, what costs are expected, whether the collaboration includes any revenue-sharing or milestone payments, and whether additional companies are involved in commercialization planning. The post also did not disclose any timeline for commercialization decisions beyond the stated intent to support potential commercialization.